MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo
- 1 May 1995
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 34 (2) , 97-117
- https://doi.org/10.1007/bf00665783
Abstract
Ac-erbB-2 expression vector was transfected into the estrogen receptor positive (ER+) MCF-7 human breast cancer cell line to determine if overexpression of this transmembrane tyrosine kinase could increase the malignant phenotype of this cell line. Loss of transfectedc-erbB-2 expression was observed when cells were carried in medium containing estrogen. Homogeneous populations stably overexpressing levels of the 185 kDac-erbB-2 observed in the SKBR-3 a breast cancer cell line which overexpressesc-erbB-2 as a result of gene amplification could be obtained by continually maintaining the transfected cell lines in estrogen-free conditions. Levels of constitutively activatedc-erbB-2 varied among clonal isolates. Whereas some over-expressing lines did acquire the ability to form transient tumor nodules in ovariectomized nude mice without estrogen supplementation, as well as in mice that received the antiestrogen tamoxifen, one cell line that exhibited the highest levels of constitutively activatedc-erbB-2 was able to form static tumors of a larger size under both conditions. This same cell line formed progressively growing tumors in estrogen-supplemented mice that were much larger than observed in mice injected with control cell lines, and also showed reduced sensitivity to antiestrogensin vitro, but it continued to have a low metastatic phenotype. These results suggest that signal transduction mediated by thec-erbB-2 tyrosine kinase can partially overcome the estrogen dependence of ER+ breast cancer cells for growth and thatc-erbB-2 overexpression confers a selective advantage to such cells in the absence of estrogen.Keywords
This publication has 54 references indexed in Scilit:
- A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.Molecular and Cellular Biology, 1993
- Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.Proceedings of the National Academy of Sciences, 1993
- Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.Proceedings of the National Academy of Sciences, 1993
- An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation.Molecular and Cellular Biology, 1992
- Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancerBritish Journal of Cancer, 1992
- c-erbB-2 oncogene as a prognostic marker in breast cancerBritish Journal of Cancer, 1991
- c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodesBritish Journal of Cancer, 1991
- A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization.Molecular and Cellular Biology, 1991
- Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation.Molecular and Cellular Biology, 1989
- High-efficiency transformation of mammalian cells by plasmid DNA.Molecular and Cellular Biology, 1987